Evidence map›Paper›PMID 33316684›Full record

ReviewSurgical oncology2021

A review of tumor-specific fluorescence-guided surgery for colorectal cancer.

Hannah M Hollandsworth, Michael A Turner, Robert M Hoffman, Michael Bouvet

Open access · greenAbstract readReview
In one paragraph

Review in Surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Hannah M HollandsworthDepartment of Surgery, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Michael A TurnerDepartment of Surgery, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Robert M HoffmanDepartment of Surgery, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego, San Diego, CA, USA; AntiCancer Inc., San Diego, CA, USA; VA San Diego Healthcare System, San Diego, CA, USA.
Michael BouvetDepartment of Surgery, University of California San Diego, San Diego, CA, USA; Moores Cancer Center, University of California San Diego, San Diego, CA, USA; VA San Diego Healthcare System, San Diego, CA, USA. Electronic address: mbouvet@ucsd.edu.
University of California, San Diego · USAntiCancer (United States) · USVA San Diego Healthcare System · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Development of Near Infrared Fluorescence-Guided Surgical Navigation and Tumor Specific Photoimmunotherapy for Improved Outcomes for GI CancersI01BX003856 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2018 to 2022
–
CMA- Marker-assisted prevention and risk stratification (MAPRS): Mucin signatures and molecular imaging for the early detection of colorectal cancer.I01BX004494 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI BOUVET, MICHAEL · 2020 to 2023
–
BLRD VA I01 BX003856BLRD VA I01 BX004494NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

The present study reviews the use of tumor-specific antibodies conjugated to fluorescent dyes in preclinical and clinical studies to enhance visualization of primary tumors and metastases for fluorescence-guided surgery (FGS) in colorectal cancer (CRC). A search strategy was developed using the peer-reviewed National Center for Biotechnology Information (NCBI) database on PubMed. Studies using tumor-specific fluorescence imaging and FGS techniques on murine models of colorectal cell lines or patient-derived orthotopic xenograft (PDOX) colorectal cancer are reviewed. A total of 24 articles were identified that met the inclusion criteria, 21 preclinical and 3 clinical trials. The most widely used target antigen in preclinical and clinical trials was carcinoembryonic antigen (CEA). Mouse studies and clinical studies have demonstrated that the use of FGS in CRC can aid in decreased residual tumor and decreased rates of recurrence. As the mainstay of colorectal cancer treatment is surgery, the addition of intraoperative fluorescence imaging can help locate tumor margins, visualize occult micro-metastases, drive surgical decision making and improve patient outcomes.

Indexed as

FluorescenceColorectal NeoplasmsFluorescent DyesHumansOptical ImagingSurgery, Computer-AssistedFluorescent DyesColorectal cancerFluorescence-guided surgeryTumor-specific antibodies

Identifiers

PMID33316684
PMCPMC7855598
OpenAlexW3107288583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.